One side of the study is kept in the dark — here is why that side is you, what it protects against, and where the design falls short.
A single blind study is a clinical trial in which participants do not know which treatment they are receiving — the experimental drug, an existing treatment, or a placebo — while the researchers do know. The blinded side is almost always the participant, because participant expectations are a major source of bias in medical research.
Blinding sounds like secrecy, but it is disclosed secrecy: the consent document tells you the study is blinded, tells you the possible assignments and their probabilities, and you agree to not knowing as part of enrollment. What blinding protects is the data — and ultimately the patients who will rely on the study's answer. Here is how the design works, where it is used, and its known weakness.
At enrollment, participants are randomly assigned to a study arm — treatment or control. In a single blind design, the study team knows your assignment, but everything you receive is made indistinguishable: identical capsules or injections, identical visit schedules, identical procedures for every arm. Pharmacy staff prepare the doses so that nothing about appearance, taste, or timing gives the assignment away.
Your experience as a participant is the same as in any trial: screening, consent, scheduled visits, monitoring. The only difference is a question you cannot get answered until the end — many studies unblind participants after the trial closes, and the consent document says whether and when you will be told. Compensation never depends on your arm; you are paid for time and visits, at identical rates in every group, as covered in our pay guide.
Because expectation changes outcomes. People who know they got the real drug tend to report feeling better, notice benefits, and stick with the study — the placebo effect. People who know they got the placebo report less improvement and drop out more. Neither response reflects the drug's chemistry, but both land in the data, and both can bury or fake a real treatment effect.
Blinding removes that distortion at its source. When no participant knows their assignment, expectation effects fall evenly across every arm and cancel out in the comparison. Self-reported outcomes — pain scores, mood scales, sleep quality, symptom diaries — are the measurements most vulnerable to expectation, which is why trials measuring them are almost never run unblinded.
Blinding also protects behavior, not just reporting. Participants who believe they are on placebo are more likely to skip doses, seek other treatments on the side, or drop out entirely — all of which quietly reshape the groups being compared. Keeping everyone equally uncertain keeps everyone equally engaged, which preserves both the data and the fairness of the comparison.
Join the free email alert — we watch the NIH registry weekly so you don't have to.
Get trial alertsImagine a trial testing a new tablet for chronic knee pain, recruiting at research sites from Kansas City to Durham. Two hundred participants are randomized: half receive the active tablet, half an identical-looking placebo. Participants are blinded; the study clinicians know each assignment because they are titrating doses and watching for a specific side effect profile that requires knowing who got what.
Every two weeks, participants rate their pain on a standard scale. If the active group improves meaningfully more than the placebo group, that gap is evidence the drug works beyond expectation effects — because both groups carried the same hopes into their ratings. Without blinding, a skeptic could argue the treated group simply expected relief and rated accordingly. The blind is what makes the comparison mean something.
The single blind design has a known gap: the researchers still know. A clinician who knows you are on the active drug may unconsciously probe harder for improvement, grade ambiguous results more favorably, or handle side effect reports differently. This is observer bias, and it does not require bad faith — it is simply what human attention does with an expectation.
The fix is to blind both sides. In a double blind study, neither participants nor the study staff assessing outcomes know assignments, which is why double blinding is the gold standard whenever it is feasible. Single blind designs persist where staff blinding is impossible — a surgical procedure versus physical therapy, or a device the clinician must operate — or where the outcome is a hard lab value that observer bias cannot bend. Both designs sit inside the broader framework of randomized controlled trials.
For you as a participant, the practical differences between the two designs are small: the schedule, the procedures, and the pay structure are set by the protocol, not by the blinding level. What changes is how much weight the results will carry — and, in a single blind study, the knowledge that the person drawing your blood knows something you do not. If that asymmetry bothers you, ask the team why this study is not double blind; a legitimate answer usually takes one sentence.
Get an email when a new clinical trial starts recruiting within 30 miles of your ZIP code. No spam — only real studies from the NIH registry.